Various time intervals have been reported in clinical studies describing the use of PSMA‐targeted agents for primary cancer identification; for example, an interval of 17 h for 99mTc‐PSMA I&S [14], 24 h for 111In‐PSMA‐I&T [12], OTL78 [9] and IS‐002 [8], and 72 h for IR800‐IAB2M [11]. This evidence concerns the gene FOLH1 and cancer.